Treatment-related AEs associated with lenalidomide that occurred in more than 10% of patients (n = 32)
| Adverse event . | Toxicity grade* . | ||||
|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | Total . | |
| Hematologic | |||||
| Anemia | 7 (22) | 6 (19) | 13 (41) | ||
| Leukopenia | 2 (6) | 4 (13) | 1 (3) | 7 (22) | |
| Constitutional | |||||
| Fatigue | 8 (25) | 4 (13) | 7 (22) | 18 (59) | |
| Pain/burn | 2 (6) | 9 (28) | 11 (34) | ||
| Skin | |||||
| Flares/erythema | 2 (6) | 7 (22) | 8 (25) | ||
| Infection | 1 (3) | 7 (22) | 3 (9) | 11 (34) | |
| Gastrointestinal | |||||
| Nausea/vomiting | 4 (13) | 4 (13) | |||
| Anorexia/weight loss | 3 (9) | 2 (6) | 5 (16) | ||
| Constipation/diarrhea | 6 (19) | 5 (16) | 11 (34) | ||
| Neurologic | |||||
| Neuropathy (sensory/motor) | 4 (13) | 2 (6) | 6 (19) | ||
| Edema | 7 (22) | 8 (25) | 15 (47) | ||
| Hypoalbuminemia | 5 (16) | 4 (13) | 9 (28) | ||
| Adverse event . | Toxicity grade* . | ||||
|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | Total . | |
| Hematologic | |||||
| Anemia | 7 (22) | 6 (19) | 13 (41) | ||
| Leukopenia | 2 (6) | 4 (13) | 1 (3) | 7 (22) | |
| Constitutional | |||||
| Fatigue | 8 (25) | 4 (13) | 7 (22) | 18 (59) | |
| Pain/burn | 2 (6) | 9 (28) | 11 (34) | ||
| Skin | |||||
| Flares/erythema | 2 (6) | 7 (22) | 8 (25) | ||
| Infection | 1 (3) | 7 (22) | 3 (9) | 11 (34) | |
| Gastrointestinal | |||||
| Nausea/vomiting | 4 (13) | 4 (13) | |||
| Anorexia/weight loss | 3 (9) | 2 (6) | 5 (16) | ||
| Constipation/diarrhea | 6 (19) | 5 (16) | 11 (34) | ||
| Neurologic | |||||
| Neuropathy (sensory/motor) | 4 (13) | 2 (6) | 6 (19) | ||
| Edema | 7 (22) | 8 (25) | 15 (47) | ||
| Hypoalbuminemia | 5 (16) | 4 (13) | 9 (28) | ||
Data are n (%) of patients.
National Cancer Institute Common Toxicity Criteria version 3.0.